Toward an understanding of the pathophysiology of clear cell carcinoma of the ovary (review)

Oncology Letters

Volumn 6, Issue 5, 2013, Pages 1163-1173

  Uekuri, Chiharu ^a   Shigetomi, Hiroshi ^a   Ono, Sumire ^a   Sasaki, Yoshikazu ^a   Matsuura, Miyuki ^a   Kobayashi, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Clear cell carcinoma; Endometriosis; Estrogen receptor; HNF 1 ; Ovarian cancer

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DIPEPTIDYL PEPTIDASE IV; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBROCYSTIN; GALECTIN 3; GLUCOKINASE; GLUCOSE 6 PHOSPHATASE; GLUCOSE TRANSPORTER 2; GLUTAREDOXIN; GLYCOSYLTRANSFERASE; GLYPICAN 3; HEPATOCYTE NUCLEAR FACTOR 1BETA; JAGGED1; LECTIN; LEUCINE ZIPPER PROTEIN; LIPOCORTIN 4; MUCIN 1; NICOTINAMIDE METHYLTRANSFERASE; OCTAMER TRANSCRIPTION FACTOR 4; OSTEOPONTIN; SOMATOMEDIN BINDING PROTEIN 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TAMM HORSFALL GLYCOPROTEIN; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR HOXA10; TRANSCRIPTION FACTOR PAX2; ZINC FINGER PROTEIN;

CELL ADHESION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CLEAR CELL CARCINOMA; DETOXIFICATION; DNA METHYLATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MAPPING; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLYCOGEN SYNTHESIS; HORMONAL REGULATION; HUMAN; MICROSATELLITE INSTABILITY; OVARY CARCINOMA; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; UPREGULATION;

EID: 84884474001     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1550     Document Type: Review

References (91)

1. Pectasides D, Pectasides E, Psyrri A and Economopoulos T: Treatment issues in clear cell carcinoma of the ovary: a different entity? Oncologist 11: 1089-1094, 2006.
2. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM and Baergen R; Gynecologic Oncology Group: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21: 3194-3200, 2003.
3. Kajihara H, Yamada Y, Kanayama S, Furukawa N, NoguchiT, Haruta S, Yoshida S, Sado T, Oi H and Kobayashi H: Clear cell carcinoma of the ovary: potential pathogenic mechanisms (Review). Oncol Rep 23: 1193-1203, 2010.
4. Yamaguchi K, Mandai M, Oura T, Matsumura N, Hamanishi J, Baba T, Matsui S, Murphy SK and Konishi I: Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene29: 1741-1752, 2010.
5. Mandai M, Matsumura N, Baba T, Yamaguchi K, Hamanishi J and Konishi I: Ovarian clear cell carcinoma as a stress-responsive cancer: influence of the microenvironment on the carcinogenesis and cancer phenotype. Cancer Lett 310: 129-133, 2011.
6. Itamochi H, Kigawa J, Akeshima R, Sato S, KamazawaS, Takahashi M, Kanamori Y, Suzuki M, Ohwada M and TerakawaN: Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary. Oncology 62: 349-353, 2002.
7. Yoshida S, Furukawa N, Haruta S, Tanase Y, Kanayama S, Noguchi T, Sakata M, Yamada Y, Oi H and KobayashiH: Theoretical model of treatment strategies for clear cell carcinoma of the ovary: focus on perspectives. Cancer Treat Rev 35: 608-615, 2009.
8. Higashiura Y, Kajihara H, Shigetomi H and Kobayashi H: Identification of multiple pathways involved in the malignant transformation of endometriosis (Review). Oncol Lett4: 3-9, 2012.
9. Maeda D and Shih IeM: Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. Adv Anat Pathol 20: 45-52, 2013.
10. Toyokuni S. Mysterious link between iron overload and CDKN2A/2B. J Clin Biochem Nutr 48: 46-49, 2011.
11. Tanase Y, Yamada Y, Shigetomi H, Kajihara H, Oonogi A, Yoshizawa Y, Furukawa N, Haruta S, Yoshida S, Sado T, Oi H and Kobayashi H: Modulation of estrogenic action in clear cell carcinoma of the ovary. Exp Ther Med 3: 18-24, 2012.
12. Kajihara H, Yamada Y, Shigetomi H, Higashiura Y and Kobayashi H: The dichotomy in the histogenesis of endometriosis-associated ovarian cancer: clear cell-type versus endometrioid-type adenocarcinoma. Int J Gynecol Pathol 31: 304-312, 2012.
13. DeLair D, Oliva E, Köbel M, Macias A, Gilks CB and SoslowRA: Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. Am J Surg Pathol 35: 36-44, 2011.
14. Hecht JL, Kotsopoulos J, Hankinson SE and Tworoger SS: Relationship between epidemiologic risk factors and hormone receptor expression in ovarian cancer: results from the Nurses' Health Study. Cancer Epidemiol Biomarkers Prev 18: 1624-3160, 2009.
15. Tsuchiya A, Sakamoto M, Yasuda J, Chuma M, Ohta T, OhkiM, Yasugi T, Taketani Y and Hirohashi S: Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol163: 2503-2512, 2003.
16. Uchida H, Maruyama T, Nishikawa-Uchida S, Oda H, MiyazakiK, Yamasaki A and Yoshimura Y: Studies using an in vitro model show evidence of involvement of epithelial-mesenchymal transition of human endometrial epithelial cells in human embryo implantation. J Biol Chem 287: 4441-4450, 2012.
17. Wareing M and Greenwood SL: Review: Potassium channels in the human fetoplacental vasculature. Placenta 32: S203-S206, 2011.
18. Milne SA, Henderson TA, Kelly RW, Saunders PT, Baird DT and Critchley HO: Leukocyte populations and steroid receptor expression in human first-trimester decidua; regulation by antiprogestin and prostaglandin E analog. J Clin Endocrinol Metab90: 4315-4321, 2005.
19. Bulun SE, Cheng YH, Pavone ME, Xue Q, Attar E, TrukhachevaE, Tokunaga H, Utsunomiya H, Yin P, Luo X, LinZ, Imir G, ThungS, Su EJ and Kim JJ: Estrogen receptor-beta, estrogen receptor-alpha, and progesterone resistance in endometriosis. Semin Reprod Med 28: 36-43, 2010.
20. Akahane T, Sekizawa A, Okuda T, Kushima M, Saito H and Okai T: Disappearance of steroid hormone dependency during malignant transformation of ovarian clear cell cancer. Int J Gynecol Pathol 24: 369-376, 2005.
21. Dhingra N, Punia RS, Radotra A and Mohan H: Arias-Stella reaction in upper genital tract in pregnant and non-pregnant women: a study of 120 randomly selected cases. Arch Gynecol Obstet 276: 47-52, 2007.
22. Trpkov K, Guggisberg K and Yilmaz A: Arias-Stella reaction as a diagnostic pitfall in a bladder biopsy with endometriosis: case report and review of the pseudoneoplastic bladder lesions. Pathol Res Pract 205: 653-656, 2009.
23. Sakaki M, Hirokawa M, Sano T, Takahashi H, Tezuka K, Abe K and Sano M: Ovarian endometriosis showing decidual change and Arias-Stella reaction with biotin-containing intranuclear inclusions. Acta Cytol 47: 321-324, 2003.
24. Ohkawa K, Amasaki H, Terashima Y, Aizawa S and Ishikawa E: Clear cell carcinoma of the ovary: light and electron microscopic studies. Cancer 40: 3019-3029, 1977.
25. Kato N and Motoyama T: Overexpression of osteopontin in clear cell carcinoma of the ovary: close association with HNF-1beta expression. Histopathology 52: 682-688, 2008.
26. Matsuura M, Suzuki T and Saito T: Osteopontin is a new target molecule for ovarian clear cell carcinoma therapy. Cancer Sci101: 1828-1833, 2010.
27. Fraga-Silva RA, Costa-Fraga FP, Murça TM, et al: Angiotensin-converting enzyme 2 activation improves endothelial function. Hypertension 61: 1233-1238, 2013.
28. Min KW, Park MH, Hong SR, Lee H, Kwon SY, Hong SH, Joo HJ, Park IA, An HJ, Suh KS, Oh HK, Yoo CW, Kim MJ, Chang HK, Jun SY, Yoon HK, Chang ED, Kim DW and KimI; The Gynecologic Pathology Study Group of the Korean Society of Pathologists: Clear Cell Carcinomas of the Ovary: A Multi-Institutional Study of 129 Cases in Korea With Prognostic Significance of Emi1 and Galectin-3. Int J Gynecol Pathol 32: 3-14, 2013.
29. Oishi T, Itamochi H, Kigawa J, Kanamori Y, ShimadaM, Takahashi M, Shimogai R, Kawaguchi W, Sato S and TerakawaN: Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary. Int J Gynecol Cancer 17: 1040-1046, 2007.
30. von Wolff M, Wang X, Gabius HJ and Strowitzki T: Galectin fingerprinting in human endometrium and decidua during the menstrual cycle and in early gestation. Mol Hum Reprod 11: 189-194, 2005.
31. Noël JC, Chapron C, Borghese B, Fayt I and Anaf V: Galectin-3 is overexpressed in various forms of endometriosis. Appl Immunohistochem Mol Morphol 19: 253-257, 2011.
32. Maeda D, Ota S, Takazawa Y, Aburatani H, Nakagawa S, Yano T, Taketani Y, Kodama T and Fukayama M: Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol 22: 824-832, 2009.
33. Tamada Y, Takeuchi H, Suzuki N, Susumu N, Aoki D and IrimuraT: Biological and therapeutic significance of MUC1 with sialoglycans in clear cell adenocarcinoma of the ovary. Cancer Sci98: 1586-1591, 2007.
34. Vlad AM, Diaconu I and Gantt KR: MUC1 in endometriosis and ovarian cancer. Immunol Res 36: 229-236, 2006.
35. Carson DD, Julian J, Lessey BA, Prakobphol A and Fisher SJ: MUC1 is a scaffold for selectin ligands in the human uterus. Front Biosci 11: 2903-2908, 2006.
36. Kim A, Enomoto T, Serada S, Ueda Y, Takahashi T, RipleyB, Miyatake T, Fujita M, Lee CM, Morimoto K, Fujimoto M, Kimura T and Naka T: Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. Int J Cancer 125: 2316-2322, 2009.
37. Ponnampalam AP and Rogers PA: Cyclic changes and hormonal regulation of annexin IV mRNA and protein in human endometrium. Mol Hum Reprod 12: 661-669, 2006.
38. Jiang YL, Li B, Xing FQ, Wang F and Feng JH: Study on the relationship between altered expression of annexin A4 and endometrial receptivity during the implantation window in infertile patients with endometriosis. Zhonghua Fu Chan Ke Za Zhi 47: 324-327, 2012 (In Chinese).
39. Sugita S, Morishita Y, Kano J, Furuya S, Shiba-Ishii A and NoguchiM: IGFBP-1 is expressed specifically in ovarian clear cell adenocarcinoma. Histopathology 58: 729-738, 2011.
40. Tan DS, Iravani M, McCluggage WG, Lambros MB, Milanezi F, Mackay A, Gourley C, Geyer FC, Vatcheva R, Millar J, ThomasK, Natrajan R, Savage K, Fenwick K, Williams A, Jameson C, El-Bahrawy M, Gore ME, Gabra H, Kaye SB, Ashworth A and Reis-Filho JS: Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin Cancer Res 17: 1521-1534, 2011.
41. Howell NR, Zheng W, Cheng L, Tornos C, Kane P, Pearl M, Chalas E and Liang SX: Carcinomas of ovary and lung with clear cell features: can immunohistochemistry help in differential diagnosis? Int J Gynecol Pathol 26: 134-140, 2007.
42. Pacchiarotti A, Caserta D, Sbracia M and Moscarini M: Expression of oct-4 and c-kit antigens in endometriosis. Fertil Steril 95: 1171-1173, 2011.
43. Ghosh D and Sengupta J: Endocrine and paracrine correlates of endometrial receptivity to blastocyst implantation in the human. Indian J Physiol Pharmacol 48: 6-30, 2004.
44. Li B, Jin H, Yu Y, Gu C, Zhou X, Zhao N and Feng Y: HOXA10 is overexpressed in human ovarian clear cell adenocarcinoma and correlates with poor survival. Int J Gynecol Cancer 19: 1347-1352, 2009.
45. Zanatta A, Rocha AM, Carvalho FM, Pereira RM, Taylor HS, Motta EL, Baracat EC and Serafini PC: The role of the Hoxa10/HOXA10 gene in the etiology of endometriosis and its related infertility: a review. J Assist Reprod Genet 27: 701-710, 2010.
46. Kobayashi H, Yamada Y, Kanayama S, Furukawa N, NoguchiT, Haruta S, Yoshida S, Sakata M, Sado T and Oi H: The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol Cancer 19: 471-479, 2009.
47. Salameh W, Helliwell JP, Han G, McPhaul L and Khorram O: Expression of endometrial glycogen synthase kinase-3beta protein throughout the menstrual cycle and its regulation by progesterone. Mol Hum Reprod 12: 543-549, 2006.
48. von Wolff M, Ursel S, Hahn U, Steldinger R and Strowitzki T: Glucose transporter proteins (GLUT) in human endometrium: expression, regulation, and function throughout the menstrual cycle and in early pregnancy. J Clin Endocrinol Metab 88: 3885-3892, 2003.
49. Senkel S, Lucas B, Klein-Hitpass L and Ryffel GU: Identification of target genes of the transcription factor HNF1beta and HNF1alpha in a human embryonic kidney cell line. Biochim Biophys Acta 1731: 179-190, 2005.
50. Xu JM, Wang Y, Ge FJ, Lin L, Liu ZY and Sharma MR: Severe irinotecan-induced toxicity in a patient with UGT1A1*28 and UGT1A1*6 polymorphisms. World J Gastroenterol 19: 3899-3903, 2013.
51. Tang SW, Yang TC, Lin WC, Chang WH, Wang CC, LaiMK and Lin JY: Nicotinamide N-methyltransferase induces cellular invasion through activating matrix metalloproteinase-2 expression in clear cell renal cell carcinoma cells. Carcinogenesis32: 138-145, 2011.
52. Salleh N, Baines DL, Naftalin RJ and Milligan SR: The hormonal control of uterine luminal fluid secretion and absorption. JMembr Biol 206: 17-28, 2005.
53. Kerschner JL, Harris A. Transcriptional networks driving enhancer function in the CFTR gene. Biochem J446: 203-212, 2012.
54. Ferrè S, Veenstra GJ, Bouwmeester R, Hoenderop JG, Bindels RJ. HNF-1B specifically regulates the transcription of the γa-subunit of the Na+/K+-ATPase. Biochem Biophys Res Commun 404: 284-290, 2011.
55. Kobayashi H, Kajiwara H, Kanayama S, Yamada Y, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sakata M, Sado T, Oi H. Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (Review). Oncol Rep 22: 233-240, 2009.
56. Gütgemann I, Lehman NL, Jackson PK and Longacre TA: Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma. Mod Pathol 21: 445-454, 2008.
57. Kuo KT, Mao TL, Chen X, Feng Y, Nakayama K, Wang Y, GlasR, Ma MJ, Kurman RJ, Shih IeM and Wang TL: DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res 16: 1997-2008, 2010.
58. Ju W, Yoo BC, Kim IJ, Kim JW, Kim SC and Lee HP: Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays. Oncol Res 18: 47-56, 2009.
59. Ozdemir F, Altinisik J, Karateke A, Coksuer H and Buyru N: Methylation of tumor suppressor genes in ovarian cancer. Exp Ther Med 4: 1092-1096, 2012.
60. Ho CM, Lai HC, Huang SH, Chien TY, Lin MC and Chang SF: Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma. Eur J Clin Invest 40: 310-318, 2010.
61. Akatsuka S, Yamashita Y, Ohara H, Liu YT, Izumiya M, AbeK, Ochiai M, Jiang L, Nagai H, Okazaki Y, Murakami H, SekidoY, Arai E, Kanai Y, Hino O, Takahashi T, Nakagama H and ToyokuniS: Fenton reaction induced cancer in wild type rats recapitulates genomic alterations observed in human cancer. PLoS One 7: e43403, 2012.
62. Choi YL, Kang SY, Shin YK, Choi JS, Kim SH, Lee SJ, BaeDS and Ahn G: Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas. Virchows Arch448: 331-336, 2006.
63. Vestergaard AL, Thorup K, Knudsen UB, Munk T, Rosbach H, Poulsen JB, Guldberg P and Martensen PM: Oncogenic events associated with endometrial and ovarian cancers are rare in endometriosis. Mol Hum Reprod 17: 758-761, 2011.
64. Zannoni GF, Morassi F, Prisco MG, De Stefano I, VelloneVG, Arena V, Scambia G and Gallo D: Clinicopathologic and immunohistochemical features of ovarian clear cell carcinomas in comparison with type I and type II tumors. Int J Gynecol Pathol31: 507-516, 2012.
65. Eltabbakh GH, Mount SL, Beatty B, Simmons-Arnold L and Cooper K: Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma. J Surg Oncol 93: 379-386, 2006.
66. Axiotis CA, Guarch R, Merino MJ, Laporte N and NeumannRD: P-glycoprotein expression is increased in human secretory and gestational endometrium. Lab Invest 65: 577-581, 1991.
67. Nomura H, Tamada Y, Miyagi T, Suzuki A, Taira M, Suzuki N, Susumu N, Irimura T and Aoki D: Expression of NEU3 (plasma membrane-associated sialidase) in clear cell adenocarcinoma of the ovary: its relationship with T factor of pTNM classification. Oncol Res 16: 289-297, 2006.
68. Liu P, Khurana A, Rattan R, He X, Kalloger S, Dowdy S, GilksB and Shridhar V: Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer. Cancer Res 69: 4843-4850, 2009.
69. Collins Y, Dicioccio R, Keitz B, Lele S and Odunsi K: Methylation of death-associated protein kinase in ovarian carcinomas. Int J Gynecol Cancer 16: 195-199, 2006.
70. Song H, Kwan SY, Izaguirre DI, Zu Z, Tsang YT, Tung CS, KingER, Mok SC, Gershenson DM and Wong KK: PAX2 Expression in Ovarian Cancer. Int J Mol Sci 14: 6090-6105, 2013.
71. Cai KQ, Caslini C, Capo-chichi CD, Slater C, Smith ER, WuH, Klein-Szanto AJ, Godwin AK and Xu XX: Loss of GATA4 and GATA6 expression specifies ovarian cancer histological subtypes and precedes neoplastic transformation of ovarian surface epithelia. PLoS One 4: e6454, 2009.
72. Blanco D, Vicent S, Fraga MF, Fernandez-Garcia I, Freire J, Lujambio A, Esteller M, Ortiz-de-Solorzano C, Pio R, LecandaF and Montuenga LM: Molecular analysis of a multistep lung cancer model induced by chronic inflammation reveals epigenetic regulation of p16 and activation of the DNA damage response pathway. Neoplasia 9: 840-852, 2007.
73. McKie AB, Vaughan S, Zanini E, Okon IS, Louis L, de SousaC, Greene MI, Wang Q, Agarwal R, Shaposhnikov D, Wong JL, Gungor H, Janczar S, El-Bahrawy M, Lam EW, Chayen NE and Gabra H: The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer. Cancer Discov 2: 156-171, 2012.
74. Ren F, Wang D, Jiang Y and Ren F: Epigenetic inactivation of hMLH1 in the malignant transformation of ovarian endometriosis. Arch Gynecol Obstet 285: 215-221, 2012.
75. Coffinier C, Thepot D, Babinet C, Yaniv M and Barra J: Essential role for the homeoprotein vHNF1/HNF1beta in visceral endoderm differentiation. Development 126: 4785-4794, 1999.
76. Horikawa Y, Iwasaki N, Hara M, Furuta H, Hinokio Y, CockburnBN, Lindner T, Yamagata K, Ogata M, Tomonaga O, Kuroki H, Kasahara T, Iwamoto Y and Bell GI: Mutation in hepatocyte nuclear factor-1β gene (TCF2) associated with MODY. Nat Genet 17: 384-385, 1997.
77. Ogata K, Shimamura Y, Hamada K, Hisa M, Bun M, OkadaN, Inoue K, Taniguchi Y, Ishihara M, Kagawa T, Horino T, FujimotoS and Terada Y: Upregulation of HNF-1β during experimental acute kidney injury plays a crucial role in renal tubule regeneration. Am J Physiol Renal Physiol 303: F689-F699, 2012.
78. D'Angelo A, Bluteau O, Garcia-Gonzalez MA, Gresh L, DoyenA, Garbay S, Robine S and Pontoglio M: Hepatocyte nuclear factor 1alpha and beta control terminal differentiation and cell fate commitment in the gut epithelium. Development 137: 1573-1582, 2010.
79. Avni FE and Hall M: Renal cystic diseases in children: new concepts. Pediatr Radiol 40: 939-946, 2010.
80. Zhou XH, Hui ZY and Li Y: Clinical and pathological features of a neonate with autosomal recessive polycystic kidney disease caused by a nonsense PKHD1 mutation. World J Pediatr 9: 76-79, 2013.
81. Serafini-Cessi F, Monti A and Cavallone D: N-Glycans carried by Tamm-Horsfall glycoprotein have a crucial role in the defense against urinary tract diseases. Glycoconj J 22: 383-394, 2005.
82. Sutherland KD, Lindeman GJ, Choong DY, Wittlin S, BrentzellL, Phillips W, Campbell IG and Visvader JE: Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene 23: 7726-7733, 2004.
83. Dimitriadis E, Stoikos C, Tan YL and Salamonsen LA: Interleukin 11 signaling components signal transducer and activator of transcription 3 (STAT3) and suppressor of cytokine signaling 3 (SOCS3) regulate human endometrial stromal cell differentiation. Endocrinol 147: 3809-3817, 2006.
84. Oktem G, Sanci M, Bilir A, Yildirim Y, Kececi SD, Ayla S and Inan S: Cancer stem cell and embryonic development-associated molecules contribute to prognostic significance in ovarian cancer. Int J Gynecol Cancer 22: 23-29, 2012.
85. Yamada Y, Shigetomi H, Onogi A, Haruta S, Kawaguchi R, Yoshida S, Furukawa N, Nagai A, Tanase Y, Tsunemi T, Oi H and Kobayashi H: Redox-active iron-induced oxidative stress in the pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol Cancer 21: 1200-1207, 2011.
86. Haruta S, Furukawa N, Yoshizawa Y, Tsunemi T, Nagai A, Kawaguchi R, Tanase Y, Yoshida S and Kobayashi H: Molecular genetics and epidemiology of epithelial ovarian cancer. Oncol Rep 26: 1347-1356, 2011.
87. Kato N, Tamura G and Motoyama T: Hypomethylation of hepatocyte nuclear factor-1beta (HNF-1beta) CpG island in clear cell carcinoma of the ovary. Virchows Arch 452: 175-180, 2008.
88. Shigetomi H, Higashiura Y, Kajihara H and Kobayashi H: A potential link of oxidative stress and cell cycle regulation for development of endometriosis. Gynecol Endocrinol 28: 897-902, 2012.
89. Cameron RI, Ashe P, O'Rourke DM, Foster H and McCluggageWG: A panel of immunohistochemical stains assists in the distinction between ovarian and renal clear cell carcinoma. Int J Gynecol Pathol 22: 272-276, 2003.
90. Brinkman JA and El-Ashry D: ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers. J Mammary Gland Biol Neoplasia 14: 67-78, 2009.
91. Iida Y, Aoki K, Asakura T, Ueda K, Yanaihara N, TakakuraS, Yamada K, Okamoto A, Tanaka T and Ohkawa K: Hypoxia promotes glycogen synthesis and accumulation in human ovarian clear cell carcinoma. Int J Oncol 40: 2122-2130, 2012.